NYSE:ANVS Annovis Bio (ANVS) Stock Price, News & Analysis $7.87 +0.01 (+0.13%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$7.45▼$7.9250-Day Range$5.27▼$15.4252-Week Range$4.53▼$22.49Volume129,734 shsAverage Volume913,565 shsMarket Capitalization$87.92 millionP/E RatioN/ADividend YieldN/APrice Target$33.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Annovis Bio alerts: Email Address Annovis Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside326.9% Upside$33.60 Price TargetShort InterestBearish13.88% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.24Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.53) to ($1.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.75 out of 5 starsMedical Sector597th out of 910 stocksPharmaceutical Preparations Industry276th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingAnnovis Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAnnovis Bio has only been the subject of 3 research reports in the past 90 days.Read more about Annovis Bio's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted13.88% of the outstanding shares of Annovis Bio have been sold short.Short Interest Ratio / Days to CoverAnnovis Bio has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Annovis Bio has recently increased by 4.73%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAnnovis Bio does not currently pay a dividend.Dividend GrowthAnnovis Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ANVS. Previous Next 1.8 News and Social Media Coverage News SentimentAnnovis Bio has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Annovis Bio this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for ANVS on MarketBeat in the last 30 days. This is a decrease of -90% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Annovis Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -38% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Annovis Bio insiders have not sold or bought any company stock.Percentage Held by Insiders38.30% of the stock of Annovis Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.83% of the stock of Annovis Bio is held by institutions.Read more about Annovis Bio's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Annovis Bio are expected to grow in the coming year, from ($2.53) to ($1.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Annovis Bio is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Annovis Bio is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Annovis Bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsThe $15 "Insider Secret" That Could Save Your RetirementWhat if I told you there's a $15 stock that a billionaire insider just poured $47 MILLION into? That's right. You can grab shares of this potential retirement-maker for less than you'd pay for lunch.Click here to discover the name and ticker of this "$15 billionaire-backed retirement stock" >>> About Annovis Bio Stock (NYSE:ANVS)Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.Read More ANVS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANVS Stock News HeadlinesSeptember 7 at 12:44 PM | theglobeandmail.comAnnovis Bio (NYSE: ANVS) to Participate at H.C. Wainwright Investment ConferenceSeptember 7 at 12:44 PM | msn.comAnnovis Bio’s CEO to Present at H.C. Wainwright Global Investment ConferenceSeptember 7, 2024 | Behind the Markets (Ad)The $15 "Insider Secret" That Could Save Your RetirementWhat if I told you there's a $15 stock that a billionaire insider just poured $47 MILLION into? That's right. You can grab shares of this potential retirement-maker for less than you'd pay for lunch.September 5 at 1:54 PM | msn.comBioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Participate at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 5 at 8:54 AM | theglobeandmail.comAnnovis Bio (NYSE: ANVS) Expands Team in Continued Focus to Make Meaningful Impact on Lives of AD, PD PatientsSeptember 5 at 8:00 AM | globenewswire.comAnnovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4 at 1:58 AM | markets.businessinsider.comBuy Rating on Annovis Bio Amid Progress in PD and AD Drug DevelopmentSeptember 2, 2024 | ca.finance.yahoo.comANVS Sep 2024 9.000 putSeptember 7, 2024 | Behind the Markets (Ad)The $15 "Insider Secret" That Could Save Your RetirementWhat if I told you there's a $15 stock that a billionaire insider just poured $47 MILLION into? That's right. You can grab shares of this potential retirement-maker for less than you'd pay for lunch.September 2, 2024 | ca.finance.yahoo.comANVS Sep 2024 20.000 callAugust 28, 2024 | theglobeandmail.comAnnovis Bio (NYSE: ANVS) Announces Encouraging Clinical Trial Results, IP Portfolio EnhancementAugust 23, 2024 | finance.yahoo.comAnnovis Bio, Inc. (NYSE:ANVS) surges 24%; retail investors who own 56% shares profited along with insidersAugust 22, 2024 | theglobeandmail.comAnnovis Bio (NYSE: ANVS) CEO Discusses Findings of Buntanetap Alzheimer’s Study on Bell2Bell PodcastAugust 16, 2024 | theglobeandmail.comAnnovis Bio (NYSE: ANVS) Announces Q2 2024 Financial ResultsAugust 16, 2024 | msn.comBioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Announces Q2 2024 Financial Results, Provides Update Showing ‘Productive’ Recent MonthsAugust 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Annovis Bio Amid Promising Buntanetap Trials and Stable FinancialsAugust 15, 2024 | uk.investing.comAnnovis Bio shares jump on bullish EF Hutton ratingAugust 15, 2024 | msn.comStudies Show Protein, Reelin, Protects Brain Against Alzheimer’s, AgingSee More Headlines Receive ANVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Annovis Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/15/2024Today9/07/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:ANVS CUSIPN/A CIK1477845 Webwww.annovisbio.com Phone610-727-3913FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Stock Price Target$33.60 High Stock Price Target$67.00 Low Stock Price Target$9.00 Potential Upside/Downside+326.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($5.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-56,200,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-876.22% Return on Assets-374.65% Debt Debt-to-Equity RatioN/A Current Ratio1.24 Quick Ratio1.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.13) per share Price / Book-60.54Miscellaneous Outstanding Shares11,171,000Free Float6,893,000Market Cap$87.92 million OptionableOptionable Beta1.73 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesDr. Maria L. Maccecchini Ph.D. (Age 73)Founder, CEO, President, Interim Principal Financial Officer & Executive Director Comp: $681.2kDr. Cheng Fang Ph.D.Senior Vice President of Research & DevelopmentMs. Eve M. Damiano M.S.RAC, Senior Vice President of Regulatory OperationsMs. Melissa GainesSenior Vice President of Clinical OperationsKey CompetitorsbioteNASDAQ:BTMDG1 TherapeuticsNASDAQ:GTHXAura BiosciencesNASDAQ:AURANkartaNASDAQ:NKTXOrganogenesisNASDAQ:ORGOView All CompetitorsInstitutional OwnershipAffinity Asset Advisors LLCSold 72,900 shares on 8/15/2024Ownership: 0.000%XTX Topco LtdBought 19,907 shares on 8/12/2024Ownership: 0.178%Greenwich Wealth Management LLCBought 2,500 shares on 8/9/2024Ownership: 0.135%View All Institutional Transactions ANVS Stock Analysis - Frequently Asked Questions How have ANVS shares performed this year? Annovis Bio's stock was trading at $18.70 at the start of the year. Since then, ANVS shares have decreased by 57.9% and is now trading at $7.87. View the best growth stocks for 2024 here. How were Annovis Bio's earnings last quarter? Annovis Bio, Inc. (NYSE:ANVS) announced its quarterly earnings results on Thursday, August, 15th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.19. When did Annovis Bio IPO? Annovis Bio (ANVS) raised $10 million in an initial public offering on Wednesday, January 29th 2020. The company issued 1,400,000 shares at a price of $6.00-$8.00 per share. ThinkEquity (a division of Fordham Financial Management, Inc. ) acted as the underwriter for the IPO. Who are Annovis Bio's major shareholders? Top institutional investors of Annovis Bio include XTX Topco Ltd (0.18%), Greenwich Wealth Management LLC (0.13%), Affinity Asset Advisors LLC and Concourse Financial Group Securities Inc.. Insiders that own company stock include Maria-Luisa Maccecchini and Claudine Bruck. View institutional ownership trends. How do I buy shares of Annovis Bio? Shares of ANVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Annovis Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Annovis Bio investors own include ADMA Biologics (ADMA), Bionano Genomics (BNGO), KushCo (KSHB), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Auxly Cannabis Group (CBWTF) and Novan (NOVN). This page (NYSE:ANVS) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredWhat is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annovis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annovis Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
